sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Umeclidinium

Medicine

Umeclidinium

INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Do not take if
  • Severe hypersensitivity to milk proteins
  • Hypersensitivity to umeclidinium or any of the excipients

What it is used for

Umeclidinium ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Side effects, and when to stop

The following adverse reactions are described in greater detail in other sections:

  • Paradoxical bronchospasm
  • Worsening of narrow-angle glaucoma
  • Worsening of urinary retention

Who should not take it

Umeclidinium ELLIPTA is contraindicated in the following conditions:

  • Severe hypersensitivity to milk proteins
  • Hypersensitivity to umeclidinium or any of the excipients

2 dosage and administration

The recommended dosage of Umeclidinium ELLIPTA for maintenance treatment of COPD is 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation.

  • Umeclidinium ELLIPTA should be used at the same time every day. Do not use Umeclidinium ELLIPTA more than 1 time every 24 hours.
  • No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Umeclidinium; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/umeclidinium

APA 7th

sofidex. (2026, August 3). Umeclidinium. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/umeclidinium

AMA 11th

Umeclidinium. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/umeclidinium

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.